{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Shinoda H"],"funding":["MEXT | Japan Society for the Promotion of Science","MEXT | Japan Science and Technology Agency (JST)","MEXT | Japan Society for the Promotion of Science (JSPS)","Japan Agency for Medical Research and Development","MEXT | Japan Science and Technology Agency","Japan Agency for Medical Research and Development (AMED)"],"pagination":["476"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8055673"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["4(1)"],"pubmed_abstract":["CRISPR-based nucleic-acid detection is an emerging technology for molecular diagnostics. However, these methods generally require several hours and could cause amplification errors, due to the pre-amplification of target nucleic acids to enhance the detection sensitivity. Here, we developed a platform that allows \"CRISPR-based amplification-free digital RNA detection (SATORI)\", by combining CRISPR-Cas13-based RNA detection and microchamber-array technologies. SATORI detected single-stranded RNA targets with maximal sensitivity of ~10 fM in <5 min, with high specificity. Furthermore, the simultaneous use of multiple different guide RNAs enhanced the sensitivity, thereby enabling the detection of the SARS-CoV-2 N-gene RNA at ~5 fM levels. Therefore, we hope SATORI will serve as a powerful class of accurate and rapid diagnostics."],"journal":["Communications biology"],"pubmed_title":["Amplification-free RNA detection with CRISPR-Cas13."],"pmcid":["PMC8055673"],"funding_grant_id":["JPMJCR19H5","20H05931","20he0622032h0001"],"pubmed_authors":["Shinoda H","Nakagawa R","Takahashi C","Ando J","Okazaki S","Nakano M","Taguchi Y","Nishimasu H","Noda T","Nureki O","Makino A","Watanabe R","Muramoto Y","Takahashi I"],"additional_accession":[]},"is_claimable":false,"name":"Amplification-free RNA detection with CRISPR-Cas13.","description":"CRISPR-based nucleic-acid detection is an emerging technology for molecular diagnostics. However, these methods generally require several hours and could cause amplification errors, due to the pre-amplification of target nucleic acids to enhance the detection sensitivity. Here, we developed a platform that allows \"CRISPR-based amplification-free digital RNA detection (SATORI)\", by combining CRISPR-Cas13-based RNA detection and microchamber-array technologies. SATORI detected single-stranded RNA targets with maximal sensitivity of ~10 fM in <5 min, with high specificity. Furthermore, the simultaneous use of multiple different guide RNAs enhanced the sensitivity, thereby enabling the detection of the SARS-CoV-2 N-gene RNA at ~5 fM levels. Therefore, we hope SATORI will serve as a powerful class of accurate and rapid diagnostics.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Apr","modification":"2025-04-05T10:14:44.706Z","creation":"2025-04-05T10:14:44.706Z"},"accession":"S-EPMC8055673","cross_references":{"pubmed":["33875803"],"doi":["10.1038/s42003-021-02001-8"]}}